Curanex Pharmaceuticals Inc (NASDAQ:CURX) Sees Large Increase in Short Interest

Curanex Pharmaceuticals Inc (NASDAQ:CURX) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 2,823 shares, a growth of 528.7% from the August 31st total of 449 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily volume of 31,637 shares, the short-interest ratio is currently 0.1 days.

Curanex Pharmaceuticals Trading Up 6.2%

Shares of Curanex Pharmaceuticals stock opened at $4.72 on Friday. Curanex Pharmaceuticals has a 1 year low of $3.58 and a 1 year high of $21.00. The company’s fifty day simple moving average is $4.37 and its 200-day simple moving average is $6.21. The company has a market cap of $7.42 million and a price-to-earnings ratio of -0.61.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Curanex Pharmaceuticals presently has an average rating of “Sell”.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.